Your video will play in 0 secs
- Ebola drug ZMapp was developed by a company based in San Diego
- Other companies have also been working to develop treatments for Ebola
- It's unclear whether the drug will be administered to other Ebola patients
(CNN) -- Two American missionary workers infected with the deadly Ebola virus were given an experimental drug that seems to have saved their lives.
Dr. Kent Brantly was given the medication, ZMapp, shortly after telling his doctors he thought he would die, according to a source familiar with his case. Within an hour, doctors say his symptoms -- labored breathing and a widespread rash -- dramatically improved. Nancy Writebol, another missionary working with Samaritan's Purse, received two doses of the medication and has also shown significant improvement, sources say.
As there is no proven treatment and no vaccine for Ebola, this experimental drug is raising lots of questions.
Who makes the drug?
The drug was developed by the biotech firm Mapp Biopharmaceutical Inc., which is based in San Diego. The company was founded in 2003 "to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense," according to its website.
Mapp Biopharmaceutical has been working with the National Institutes of Health and the Defense Threat Reduction Agency, an arm of the military responsible for weapons of mass destruction, to develop an Ebola treatment for several years.
Are there other experimental Ebola drugs out there?
Yes. In March, the NIH awarded a five-year $28 million grant to establish a collaboration between researchers from 15 institutions who were working to fight Ebola.
"A whole menu of antibodies have been identified as potentially therapeutic, and researchers are eager to figure out which combinations are most effective and why," a news release about the grant said.
Tekmira, a Vancouver-based company that has a $140 million contract with the U.S. Department of Defense to develop an Ebola drug, began Phase 1 trials with its drug in January. But the FDA recently halted the trial, asking for more information.
At least one potential Ebola vaccine has been tested in healthy human volunteers, according to Thomas Geisbert, a leading researcher at the University of Texas Medical Branch. And last week, the NIH announced a safety trial of another Ebola vaccine will start as early as September.
How does ZMapp work?
Antibodies are proteins used by the immune system to mark and destroy foreign, or harmful, cells. A monoclonal antibody is similar, except it's engineered in a lab so it will attach to specific parts of a dangerous cell, according to the Mayo Clinic, mimicking your immune system's natural response. Monoclonal antibodies are used to treat many different types of conditions.
This medicine is a three-mouse monoclonal antibody, meaning that mice were exposed to fragments of the Ebola virus and then the antibodies generated within the mice's blood were harvested to create the medicine.
Why did American missionary workers get the drug?
Many have asked why these two workers received the experimental drug when so many -- around 1,600 -- others in West Africa also have the virus.
Samaritan's Purse reached out to an NIH scientist who was on the ground in West Africa, according to the National Institute of Allergy and Infectious Diseases. "The scientist was able to informally answer some questions and referred them to appropriate company contacts to pursue their interest in obtaining experimental product," NIAID said.
The World Health Organization says it was not involved in the decision to treat Brantly and Writebol. Both patients had to give consent to receive the drug, knowing it had never been tested in humans before.
The process by which the medication was made available to the American patients may have fallen under the U.S. Food and Drug Administration's "compassionate use" regulation, which allows access to investigational drugs outside clinical trials.
Did doctors know it would work?
No. The drug had shown promise in primates, but even in those experiments, just eight monkeys received the treatment. In any case, the human immune system can react differently than primates', which is why drugs are required to undergo human clinical trials before being approved by government agencies for widespread use.
The two Americans' cases will be studied further to determine how the drug worked with their immune systems.
Will the drug be made available to other Ebola patients?
It's unclear. Doctors "cannot start using untested drugs in the middle of an outbreak, for various reasons," World Health Organization spokesman Gregory Hartl said.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, says scientists have to be careful about assuming this drug will work in other patients as it appears to have worked in Brantly.
"Having worked with administering antibodies for people for a really long time, that would be distinctly unusual," he told CNN. "As we all know in medicine ... you have to withhold judgment."
Does the company have more vials of the drug?
The company has very few doses ready for patient use, Fauci told CNN. "Apparently the company is trying to scale up, (but) it's not easy to scale up to very large number of doses."
Who paid for the drug and how much did it cost?
We don't know. Samaritan's Purse covered the cost of Brantly and Writebol's evacuations but did not pay for the drug, according to a spokesman.
When a patient gets an experimental drug, the drug company can donate the product under compassionate use. Mapp Biopharmaceutical Inc. might have done that in this case.
Health insurance companies typically do not pick up the tab for treatments that have not been approved by the FDA. But they would usually cover the cost of any doctor fees associated with giving the drug and any costs associated with monitoring how the drug is working.
Would this drug stop the Ebola epidemic?
If it were widely available, it certainly couldn't hurt. An effective Ebola drug could help doctors treat the deadly virus, which is killing about 60% of the people infected in West Africa. But a vaccine would be a much more effective tool in stopping this, and future, epidemics.
Vaccines are given to healthy people to prevent them from ever becoming infected. One challenge with Ebola, experts say, is that companies don't believe they could make much money from developing a vaccine, so few companies show interest.
2014年8月4日 - 更新2233 GMT（0633 HKT）
布蘭特利肯特博士給予藥物治療，ZMapp，告訴他的醫生，他以為他會死不久，據熟悉他的案件來源。不到一個小時，醫生說他的症狀 - 呼吸困難和廣泛的皮疹 - 顯著改善。南希Writebol，另一個傳教士與善普施的工作，接受兩個劑量的藥物，並也顯示顯著改善，消息人士說。
揭秘血可能救埃博拉患者 為什麼沒有一個埃博拉病毒的疫苗？ 埃博拉運輸隊說CNN報導 西部非洲的埃博拉疫情
如何ZMAP p 的工作？
很多人問，為什麼這兩名工人接受實驗藥物有那麼多- 約1600 -人在西非也有病毒。